carvedilol has been researched along with Breast Cancer in 22 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Among breast cancer patients without a CV risk treated with doxorubicin-containing chemotherapy, subclinical cardiotoxicity is prevalent and concomitant administration of low-dose candesartan might be effective to prevent an early decrease in LVEF." | 9.41 | Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin. ( Chung, WB; Lee, JE; Lee, M; Park, CS; Park, WC; Song, BJ; Youn, HJ, 2021) |
| "We expect a group of anthracycline-treated breast cancer patients exposed to carvedilol and non-hypoxic myocardial preconditioning with DHA to show less subclinical cardiotoxicity manifestations than a comparable group exposed to placebo." | 9.34 | Prevention of doxorubicin-induced Cardiotoxicity by pharmacological non-hypoxic myocardial preconditioning based on Docosahexaenoic Acid (DHA) and carvedilol direct antioxidant effects: study protocol for a pilot, randomized, double-blind, controlled tria ( Aguayo, R; Carrasco, R; Cortés, I; Erazo, M; Gormaz, JG; Hasson, D; Henriquez, P; Morales, M; Nes, K; Ramirez, MC; Ramos, C; Salas, C; Schuster, A; Sotomayor, CG, 2020) |
| "In patients with HER2-positive breast cancer treated with trastuzumab, both lisinopril and carvedilol prevented cardiotoxicity in patients receiving anthracyclines." | 9.30 | Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer. ( Bello-Matricaria, L; Fink, A; Guglin, M; Krischer, J; McCaskill-Stevens, W; Munster, PN; Tamura, R, 2019) |
| "This prospective, randomized, double-blind, placebo-controlled study sought to evaluate the role of carvedilol in preventing ANT cardiotoxicity." | 9.27 | Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial. ( Abduch, MC; Avila, MS; Ayub-Ferreira, SM; Bittencourt Viana Cruz, CB; Bittencourt, MS; Bocchi, EA; das Dores Cruz, F; de Barros Wanderley, MR; de Paula Costa, RL; Ferrari, MSM; Gonçalves Brandão, SM; Guimaraes, GV; Hajjar, LA; Higuchi-Dos-Santos, MH; Hoff, PM; Issa, VS; Kalil Filho, R; Lofrano Alves, MS; Mano, MS; Rigaud, VOC; Sahade, M, 2018) |
| "We designed a prospective, multicenter, randomized, phase II placebo-controlled clinical trial to evaluate the effects of an ACE inhibitor (lisinopril) and a BB (carvedilol phosphate-extended release) on cardiotoxicity in patients with breast cancer who are receiving adjuvant or neoadjuvant TZB therapy." | 9.24 | Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial. ( Fink, A; Guglin, M; Krischer, J; Munster, P, 2017) |
| "Prophylactic use of carvedilol may inhibit the development of anthracycline-induced cardiotoxicity, even at low doses." | 9.24 | Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity. ( Baghyari, S; Esmaili, K; Janbabai, G; Nabati, M; Yazdani, J, 2017) |
| "In this trial, 70 female patients with breast cancer who were candidates to receive doxorubicin were enrolled, from which 30 were selected randomly to receive carvedilol 6." | 9.22 | Carvedilol Administration Can Prevent Doxorubicin-Induced Cardiotoxicity: A Double-Blind Randomized Trial. ( Fazlinezhad, A; Homaei Shandiz, F; Hosseini, G; Mostafavi Toroghi, H; Tashakori Beheshti, A; Zarifian, A, 2016) |
| "To investigate the effect of low-dose carvedilol combined with candesartan in the prevention of acute and chronic cardiotoxicity of anthracycline drugs in adjuvant chemotherapy of breast cancer." | 9.17 | [Preventive effect of low-dose carvedilol combined with candesartan on the cardiotoxicity of anthracycline drugs in the adjuvant chemotherapy of breast cancer]. ( Han, YL; Liang, XF; Liu, L; Liu, YY; Liu, ZZ; Xie, XD; Zheng, ZD, 2013) |
| "To address this, we investigated the effects of carvedilol on breast cancer cell lines, in mouse models of breast cancer and in a large cohort of patients with breast cancer (n = 4014)." | 8.02 | Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients. ( Andreassen, BK; Baker, JG; Botteri, E; Chang, A; Chung, NC; Gillis, RD; Halls, ML; Pon, CK; Shackleford, DM; Sloan, EK; Ziegler, AI, 2021) |
| " Beta blockers, such as carvedilol, have been used for protection of trastuzumab cardiotoxicity but there is no definitive conclusive clinical report on their efficacy." | 7.96 | In Vivo Evaluation of Carvedilol Cardiac Protection Against Trastuzumab Cardiotoxicity. ( Ardakani, EM; Beiranvand, E; Ostad, SN; Sardari, S; Torkashvand, F; Vaziri, B, 2020) |
| " Patients at high risk of cardiotoxicity (cardiac troponin I concentrations in the upper tertile during chemotherapy) were randomized to standard care plus cardioprotection (combination carvedilol and candesartan therapy) or standard care alone." | 5.69 | Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial. ( Borley, A; Broom, A; Collins, G; Eddie, L; Everett, RJ; Fletcher, A; Guppy, A; Hall, P; Henriksen, PA; Japp, A; Joshi, SS; Lang, NN; Lewis, S; Lord, S; Maclean, M; MacPherson, IR; McKay, P; McVicars, H; Mills, NL; Newby, DE; Oikonomidou, O; Payne, JR; Primrose, L; Radford, J; Rodriguez, A; Rowntree, C; Singh, T; Stavert, H; Williams, MC, 2023) |
| "Among breast cancer patients without a CV risk treated with doxorubicin-containing chemotherapy, subclinical cardiotoxicity is prevalent and concomitant administration of low-dose candesartan might be effective to prevent an early decrease in LVEF." | 5.41 | Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin. ( Chung, WB; Lee, JE; Lee, M; Park, CS; Park, WC; Song, BJ; Youn, HJ, 2021) |
| "We expect a group of anthracycline-treated breast cancer patients exposed to carvedilol and non-hypoxic myocardial preconditioning with DHA to show less subclinical cardiotoxicity manifestations than a comparable group exposed to placebo." | 5.34 | Prevention of doxorubicin-induced Cardiotoxicity by pharmacological non-hypoxic myocardial preconditioning based on Docosahexaenoic Acid (DHA) and carvedilol direct antioxidant effects: study protocol for a pilot, randomized, double-blind, controlled tria ( Aguayo, R; Carrasco, R; Cortés, I; Erazo, M; Gormaz, JG; Hasson, D; Henriquez, P; Morales, M; Nes, K; Ramirez, MC; Ramos, C; Salas, C; Schuster, A; Sotomayor, CG, 2020) |
| "In patients with HER2-positive breast cancer treated with trastuzumab, both lisinopril and carvedilol prevented cardiotoxicity in patients receiving anthracyclines." | 5.30 | Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer. ( Bello-Matricaria, L; Fink, A; Guglin, M; Krischer, J; McCaskill-Stevens, W; Munster, PN; Tamura, R, 2019) |
| "This prospective, randomized, double-blind, placebo-controlled study sought to evaluate the role of carvedilol in preventing ANT cardiotoxicity." | 5.27 | Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial. ( Abduch, MC; Avila, MS; Ayub-Ferreira, SM; Bittencourt Viana Cruz, CB; Bittencourt, MS; Bocchi, EA; das Dores Cruz, F; de Barros Wanderley, MR; de Paula Costa, RL; Ferrari, MSM; Gonçalves Brandão, SM; Guimaraes, GV; Hajjar, LA; Higuchi-Dos-Santos, MH; Hoff, PM; Issa, VS; Kalil Filho, R; Lofrano Alves, MS; Mano, MS; Rigaud, VOC; Sahade, M, 2018) |
| "We designed a prospective, multicenter, randomized, phase II placebo-controlled clinical trial to evaluate the effects of an ACE inhibitor (lisinopril) and a BB (carvedilol phosphate-extended release) on cardiotoxicity in patients with breast cancer who are receiving adjuvant or neoadjuvant TZB therapy." | 5.24 | Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial. ( Fink, A; Guglin, M; Krischer, J; Munster, P, 2017) |
| "Prophylactic use of carvedilol may inhibit the development of anthracycline-induced cardiotoxicity, even at low doses." | 5.24 | Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity. ( Baghyari, S; Esmaili, K; Janbabai, G; Nabati, M; Yazdani, J, 2017) |
| "Cardiac CARE will examine whether cardiac biomarker monitoring identifies patients at risk of left ventricular dysfunction following anthracycline chemotherapy and whether troponin-guided treatment with combination candesartan and carvedilol therapy prevents the development of left ventricular dysfunction in these high-risk patients." | 5.22 | Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity. ( Borley, A; Broom, A; Collins, G; Guppy, A; Hall, P; Henriksen, PA; Lang, NN; Lewis, S; Lord, S; Maclean, M; MacPherson, IR; McKay, P; McVicars, H; Mills, NL; Newby, DE; Oikonomidou, O; Payne, JR; Radford, J; Rowntree, C; Scott, F, 2022) |
| "In this trial, 70 female patients with breast cancer who were candidates to receive doxorubicin were enrolled, from which 30 were selected randomly to receive carvedilol 6." | 5.22 | Carvedilol Administration Can Prevent Doxorubicin-Induced Cardiotoxicity: A Double-Blind Randomized Trial. ( Fazlinezhad, A; Homaei Shandiz, F; Hosseini, G; Mostafavi Toroghi, H; Tashakori Beheshti, A; Zarifian, A, 2016) |
| "To investigate the effect of low-dose carvedilol combined with candesartan in the prevention of acute and chronic cardiotoxicity of anthracycline drugs in adjuvant chemotherapy of breast cancer." | 5.17 | [Preventive effect of low-dose carvedilol combined with candesartan on the cardiotoxicity of anthracycline drugs in the adjuvant chemotherapy of breast cancer]. ( Han, YL; Liang, XF; Liu, L; Liu, YY; Liu, ZZ; Xie, XD; Zheng, ZD, 2013) |
| "To address this, we investigated the effects of carvedilol on breast cancer cell lines, in mouse models of breast cancer and in a large cohort of patients with breast cancer (n = 4014)." | 4.02 | Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients. ( Andreassen, BK; Baker, JG; Botteri, E; Chang, A; Chung, NC; Gillis, RD; Halls, ML; Pon, CK; Shackleford, DM; Sloan, EK; Ziegler, AI, 2021) |
| " Beta blockers, such as carvedilol, have been used for protection of trastuzumab cardiotoxicity but there is no definitive conclusive clinical report on their efficacy." | 3.96 | In Vivo Evaluation of Carvedilol Cardiac Protection Against Trastuzumab Cardiotoxicity. ( Ardakani, EM; Beiranvand, E; Ostad, SN; Sardari, S; Torkashvand, F; Vaziri, B, 2020) |
| "Herein two breast cancer cell lines, SKBr3 and BT474, overexpressing human epithelial receptor 2 (HER2), the target of the humanised antibody trastuzumab, were treated with a range of concentrations (20-2000 nM) of doxorubicin with and without trastuzumab in the presence of clinically relevant doses of the ACE inhibitor enalapril, the beta-blocker carvedilol, metformin or dexrazoxane, and cell survival determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay." | 3.83 | Effects of Administered Cardioprotective Drugs on Treatment Response of Breast Cancer Cells. ( Akabuogu, EU; Phyu, SM; Smith, TA, 2016) |
| "The use of antracycline (ANT) in breast cancer has been associated with adverse cardiac events." | 2.79 | Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: A prospective randomized controlled study with six-month follow-up. ( Bugra, Z; Ciftci, R; Cizgici, AY; Elitok, A; Kilic, L; Mercanoglu, F; Oflaz, H; Oncul, A; Oz, F; Sen, F, 2014) |
| "Cardiotoxicity is associated with the chronic use of doxorubicin leading to cardiomyopathy and heart failure." | 1.46 | Circulating miR-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients. ( Alves, MS; Ávila, MS; Ayub-Ferreira, SM; Bocchi, EA; Brandão, SM; Cruz, CB; Cruz, FD; Cunha-Neto, E; Ferreira, LR; Guimarães, GV; Issa, VS; Rigaud, VO; Santos, MH, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (59.09) | 24.3611 |
| 2020's | 9 (40.91) | 2.80 |
| Authors | Studies |
|---|---|
| Henriksen, PA | 2 |
| Hall, P | 2 |
| Oikonomidou, O | 2 |
| MacPherson, IR | 2 |
| Maclean, M | 2 |
| Lewis, S | 2 |
| McVicars, H | 2 |
| Broom, A | 2 |
| Scott, F | 1 |
| McKay, P | 2 |
| Borley, A | 2 |
| Rowntree, C | 2 |
| Lord, S | 2 |
| Collins, G | 2 |
| Radford, J | 2 |
| Guppy, A | 2 |
| Payne, JR | 2 |
| Newby, DE | 2 |
| Mills, NL | 2 |
| Lang, NN | 2 |
| Joshi, SS | 1 |
| Singh, T | 1 |
| Rodriguez, A | 1 |
| Fletcher, A | 1 |
| Everett, RJ | 1 |
| Stavert, H | 1 |
| Eddie, L | 1 |
| Primrose, L | 1 |
| Williams, MC | 1 |
| Japp, A | 1 |
| Sun, J | 1 |
| Shang, H | 1 |
| Yang, X | 1 |
| Xing, Y | 1 |
| Ozkalayci, F | 1 |
| Tanboga, IH | 1 |
| Carrasco, R | 1 |
| Ramirez, MC | 1 |
| Nes, K | 1 |
| Schuster, A | 1 |
| Aguayo, R | 1 |
| Morales, M | 1 |
| Ramos, C | 1 |
| Hasson, D | 1 |
| Sotomayor, CG | 1 |
| Henriquez, P | 1 |
| Cortés, I | 1 |
| Erazo, M | 1 |
| Salas, C | 1 |
| Gormaz, JG | 1 |
| Beiranvand, E | 2 |
| Ostad, SN | 2 |
| Ardakani, EM | 2 |
| Torkashvand, F | 2 |
| Sardari, S | 2 |
| Vaziri, B | 2 |
| Mirzaie, M | 1 |
| Zandi, F | 1 |
| Salekdeh, GH | 1 |
| Shokrgozar, MA | 1 |
| Gillis, RD | 1 |
| Botteri, E | 2 |
| Chang, A | 1 |
| Ziegler, AI | 1 |
| Chung, NC | 1 |
| Pon, CK | 1 |
| Shackleford, DM | 1 |
| Andreassen, BK | 1 |
| Halls, ML | 1 |
| Baker, JG | 2 |
| Sloan, EK | 2 |
| Lee, M | 1 |
| Chung, WB | 1 |
| Lee, JE | 1 |
| Park, CS | 1 |
| Park, WC | 1 |
| Song, BJ | 1 |
| Youn, HJ | 1 |
| De Sanctis, R | 1 |
| Viganò, A | 1 |
| Torrisi, R | 1 |
| Santoro, A | 1 |
| Guglin, M | 2 |
| Munster, P | 1 |
| Fink, A | 2 |
| Krischer, J | 2 |
| Avila, MS | 2 |
| Ayub-Ferreira, SM | 2 |
| de Barros Wanderley, MR | 1 |
| das Dores Cruz, F | 1 |
| Gonçalves Brandão, SM | 1 |
| Rigaud, VOC | 1 |
| Higuchi-Dos-Santos, MH | 1 |
| Hajjar, LA | 1 |
| Kalil Filho, R | 1 |
| Hoff, PM | 1 |
| Sahade, M | 1 |
| Ferrari, MSM | 1 |
| de Paula Costa, RL | 1 |
| Mano, MS | 1 |
| Bittencourt Viana Cruz, CB | 1 |
| Abduch, MC | 1 |
| Lofrano Alves, MS | 1 |
| Guimaraes, GV | 2 |
| Issa, VS | 2 |
| Bittencourt, MS | 1 |
| Bocchi, EA | 2 |
| Ma, Z | 1 |
| Liu, X | 1 |
| Zhang, Q | 1 |
| Yu, Z | 1 |
| Gao, D | 1 |
| Tamura, R | 1 |
| Bello-Matricaria, L | 1 |
| McCaskill-Stevens, W | 1 |
| Munster, PN | 1 |
| Barac, A | 1 |
| Blaes, A | 1 |
| Lynce, F | 1 |
| Elitok, A | 1 |
| Oz, F | 1 |
| Cizgici, AY | 1 |
| Kilic, L | 1 |
| Ciftci, R | 1 |
| Sen, F | 1 |
| Bugra, Z | 1 |
| Mercanoglu, F | 1 |
| Oncul, A | 1 |
| Oflaz, H | 1 |
| Liu, L | 1 |
| Liu, ZZ | 1 |
| Liu, YY | 1 |
| Zheng, ZD | 1 |
| Liang, XF | 1 |
| Han, YL | 1 |
| Xie, XD | 1 |
| Smith, TA | 1 |
| Phyu, SM | 1 |
| Akabuogu, EU | 1 |
| Tashakori Beheshti, A | 1 |
| Mostafavi Toroghi, H | 1 |
| Hosseini, G | 1 |
| Zarifian, A | 1 |
| Homaei Shandiz, F | 1 |
| Fazlinezhad, A | 1 |
| Rigaud, VO | 1 |
| Ferreira, LR | 1 |
| Brandão, SM | 1 |
| Cruz, FD | 1 |
| Santos, MH | 1 |
| Cruz, CB | 1 |
| Alves, MS | 1 |
| Cunha-Neto, E | 1 |
| Nabati, M | 1 |
| Janbabai, G | 1 |
| Baghyari, S | 1 |
| Esmaili, K | 1 |
| Yazdani, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity: a Randomized Clinical Trial (SPIROTOX Trial)[NCT06005259] | Phase 4 | 264 participants (Anticipated) | Interventional | 2023-10-01 | Not yet recruiting | ||
| Carvedilol Effect in Preventing Chemotherapy - Induced Cardiotoxicity. A Randomized Double Blind Study.[NCT01724450] | Phase 3 | 200 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| Phase II Placebo-controlled Trial of Lisinopril and Coreg CR® to Reduce Cardiotoxicity in Patients With Breast Cancer Receiving (Neo)Adjuvant Chemotherapy With Trastuzumab (Herceptin®)[NCT01009918] | Phase 2 | 468 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| Can Bisoprolol Administration Prevent Anthracycline-induced Cardiotoxicity?: a Double-blind Randomized Trial.[NCT05175066] | Phase 3 | 80 participants (Actual) | Interventional | 2020-11-12 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of Participants with cardiotoxicity-free survival at 750 days from baseline (NCT01009918)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm I Lisinopril | 15 |
| Arm II Coreg CR® | 24 |
| Arm III Placebo | 17 |
Number of Participants with Left Ventricular Ejection Fraction (LVEF) drop to <50% (NCT01009918)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm I Lisinopril | 5 |
| Arm II Coreg CR® | 9 |
| Arm III Placebo | 15 |
Reduction in incidence of trastuzumab-induced cardiotoxicity after 52 weeks of treatment as measured by preservation of Left Ventricular Ejection Fraction (LVEF). Number of Patients who experienced a cardiotoxicity. (NCT01009918)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm I Lisinopril | 45 |
| Arm II Coreg CR® | 43 |
| Arm III Placebo | 46 |
Measure indicates the number of patients who had an interruption of trastuzumab for any reason (NCT01009918)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm I Lisinopril | 27 |
| Arm II Coreg CR® | 24 |
| Arm III Placebo | 40 |
Quality-of-life changes as assessed by North European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30), which measures the quality of life of cancer patients. Higher score indicates higher quality of life. Score range is 0-100. The questionnaire was administered at baseline and at 52 weeks. (NCT01009918)
Timeframe: 52 weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| Arm I Lisinopril | 1 |
| Arm II Coreg CR® | 2 |
| Arm III Placebo | 5 |
1 review available for carvedilol and Breast Cancer
| Article | Year |
|---|---|
Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity.
Topics: Adrenergic beta-Antagonists; Angiotensins; Anthracyclines; Antibiotics, Antineoplastic; Breast Neopl | 2022 |
10 trials available for carvedilol and Breast Cancer
| Article | Year |
|---|---|
Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.
Topics: Adrenergic beta-Antagonists; Anthracyclines; Antibiotics, Antineoplastic; Breast Neoplasms; Cardioto | 2023 |
Prevention of doxorubicin-induced Cardiotoxicity by pharmacological non-hypoxic myocardial preconditioning based on Docosahexaenoic Acid (DHA) and carvedilol direct antioxidant effects: study protocol for a pilot, randomized, double-blind, controlled tria
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Antibiotics, Antineoplastic; Antioxidants; Bio | 2020 |
Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Antibiotics, Antineoplastic; Antihype | 2021 |
Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Antineopla | 2017 |
Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial.
Topics: Adrenergic beta-Antagonists; Adult; Antineoplastic Agents; Breast Neoplasms; Cardiotoxicity; Carvedi | 2018 |
Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial.
Topics: Adrenergic beta-Antagonists; Adult; Antineoplastic Agents; Breast Neoplasms; Cardiotoxicity; Carvedi | 2018 |
Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial.
Topics: Adrenergic beta-Antagonists; Adult; Antineoplastic Agents; Breast Neoplasms; Cardiotoxicity; Carvedi | 2018 |
Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial.
Topics: Adrenergic beta-Antagonists; Adult; Antineoplastic Agents; Breast Neoplasms; Cardiotoxicity; Carvedi | 2018 |
Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cardiotonic Agents; Carvedilol; Female; Heart; | 2019 |
Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: A prospective randomized controlled study with six-month follow-up.
Topics: Adrenergic alpha-1 Receptor Antagonists; Anthracyclines; Breast Neoplasms; Carbazoles; Carvedilol; D | 2014 |
[Preventive effect of low-dose carvedilol combined with candesartan on the cardiotoxicity of anthracycline drugs in the adjuvant chemotherapy of breast cancer].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antineoplastic Co | 2013 |
Carvedilol Administration Can Prevent Doxorubicin-Induced Cardiotoxicity: A Double-Blind Randomized Trial.
Topics: Adrenergic beta-Antagonists; Adult; Antibiotics, Antineoplastic; Breast Neoplasms; Carbazoles; Cardi | 2016 |
Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Atrial Function, Left; Biomarkers; Breast | 2017 |
11 other studies available for carvedilol and Breast Cancer
| Article | Year |
|---|---|
Effect of Cardioprotective Drugs on Chemotherapy-Induced Heart Failure and New Risk Stratification.
Topics: Antineoplastic Agents; Breast Neoplasms; Cardiotoxicity; Carvedilol; Heart Failure; Humans; Lisinopr | 2019 |
Strategies to Prevent Cardiotoxicity.
Topics: Antineoplastic Agents; Breast Neoplasms; Cardiotoxicity; Carvedilol; Humans; Lisinopril; Neoplasms; | 2019 |
In Vivo Evaluation of Carvedilol Cardiac Protection Against Trastuzumab Cardiotoxicity.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Animals; Breast Neoplasms; Cardiotoxicity; Carved | 2020 |
Proteomics Analysis of Trastuzumab Toxicity in the H9c2 Cardiomyoblast Cell Line and its Inhibition by Carvedilol.
Topics: Adrenergic beta-Antagonists; Antineoplastic Agents, Immunological; Breast Neoplasms; Cardiomyopathie | 2020 |
Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients.
Topics: Adrenergic beta-Antagonists; Animals; Antineoplastic Agents; Breast Neoplasms; Carvedilol; Cell Line | 2021 |
Re: Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients: Sympathetic nervous system activity on breast cancer: the story of migraine.
Topics: Breast Neoplasms; Carbazoles; Carvedilol; Female; Humans; Migraine Disorders; Sympathetic Nervous Sy | 2021 |
Response to the letter Re: Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients.
Topics: Breast; Breast Neoplasms; Carbazoles; Carvedilol; Female; Humans | 2021 |
Carvedilol suppresses malignant proliferation of mammary epithelial cells through inhibition of the ROS‑mediated PI3K/AKT signaling pathway.
Topics: Antioxidants; Benzo(a)pyrene; Breast; Breast Neoplasms; Carvedilol; Cell Line; Cell Proliferation; C | 2019 |
Lessons From Primary Cardiac Prevention Trials During Trastuzumab Therapy: End of One Size Fits All.
Topics: Breast Neoplasms; Cardiotoxicity; Carvedilol; Humans; Lisinopril; Trastuzumab | 2019 |
Effects of Administered Cardioprotective Drugs on Treatment Response of Breast Cancer Cells.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antineoplastic Combined Chemo | 2016 |
Circulating miR-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients.
Topics: Biomarkers; Breast Neoplasms; Carbazoles; Cardiotoxicity; Carvedilol; Doxorubicin; Female; Humans; M | 2017 |